Trastuzumab and Doxorubicin Sequential Administration Increases Oxidative Stress and Phosphorylation of Connexin 43 on Ser368.

Abstract

Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancer cases, causing a more aggressive tumour growth and poor prognosis. Trastuzumab, the humanized antibody targeted to HER2, increased the life expectancy of patients, but severe cardiotoxicity emerged as a long-term adverse effect. Clinical evidence highlights that Trastuzumab-induced cardiotoxicity drastically increases in association with Doxorubicin; however, the exact mechanisms involved remain incompletely understood. In order to analyse the molecular mechanisms involved and the possible adaptative responses to Trastuzumab and Doxorubicin treatment, in this study, H9c2 cardiomyoblasts were used. Results showed that Trastuzumab and Doxorubicin sequential administration in cardiomyoblast increased cytosolic and mitochondrial ROS production, intracellular calcium dysregulation, mitochondrial membrane depolarization, and the consequent apoptosis, induced by both Trastuzumab and Doxorubicin alone. Furthermore, in these conditions, we observed increased levels of Connexin43 phosphorylated on Ser368 (pCx43). Since phosphorylation on Ser368 decreases gap junction intracellular communication, thus reducing the spread of death signals to adjacent cells, we hypothesized that the increase in pCx43 could be an adaptative response implemented by cells to defend neighbouring cells by Trastuzumab and Doxorubicin sequential administration. However, the other side of the coin is the resulting conduction abnormalities.

• Authors: Michela Pecoraro, Stefania Marzocco, Silvia Franceschelli, Ada Popolo
• Journal: International journal of molecular sciences (Int J Mol Sci) Vol. 23 Issue 12 (Jun 07 2022) ISSN: 1422-0067 [Electronic] Switzerland
• PMID: 35742818 (Publication Type: Journal Article)

Chemical References

• Connexin 43
• Doxorubicin
• Receptor, ErbB-2
• Trastuzumab

Topics

• Breast Neoplasms (metabolism)
• Cardiotoxicity (drug therapy, etiology)
• Connexin 43 (metabolism)
• Doxorubicin (adverse effects)
• Female
• Humans
• Oxidative Stress
• Phosphorylation
• Receptor, ErbB-2 (metabolism)
• Trastuzumab (adverse effects)